{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Prelude Therapeutics, Inc.
Prelude Therapeutics Hits New 52-Week High of $5.67, Up 527.79%
Prelude Therapeutics, Inc. has achieved a new 52-week high, reflecting strong performance with a 34.6% increase over the past year. The company reported a 155.5% rise in net sales, totaling USD 10.22 million for the half-year, and has shown consistent improvement over three consecutive quarters.
Prelude Therapeutics Experiences Revision in Its Stock Evaluation Amid Mixed Financial Trends
Prelude Therapeutics, Inc. has reported a mixed financial performance for the quarter ending June 2025, with increased net profit and sales but significant challenges in operating cash flow and return on capital employed. Despite these hurdles, the company has outperformed the S&P 500 over the past year.
Prelude Therapeutics Hits New 52-Week High of $4.22, Marking Significant Milestone
Prelude Therapeutics, Inc. has achieved a new 52-week high of USD 4.22, significantly up from its low of USD 0.61. Despite this milestone, the company has shown modest one-year performance and remains loss-making, with a market capitalization of USD 71 million and no dividend yield.
Is Prelude Therapeutics, Inc. technically bullish or bearish?
As of September 8, 2025, Prelude Therapeutics, Inc. shows a mildly bullish trend supported by positive MACD and moving averages, despite mixed signals from Bollinger Bands and underperformance compared to the S&P 500.
Is Prelude Therapeutics, Inc. overvalued or undervalued?
As of November 6, 2024, Prelude Therapeutics, Inc. is considered risky and overvalued due to negative financial metrics, including a Price to Book Value of 0.56 and significant declines in stock performance compared to the S&P 500.
Is Prelude Therapeutics, Inc. overvalued or undervalued?
As of November 6, 2024, Prelude Therapeutics, Inc. is considered a risky investment due to its negative financial metrics, including a Price to Book Value of 0.56, an EV to EBITDA ratio of 0.28, and a troubling Return on Equity of -123.89%, alongside a significant 78.01% decline in stock price over the past year.
Is Prelude Therapeutics, Inc. technically bullish or bearish?
As of June 17, 2025, the market trend is mildly bearish due to daily moving averages indicating bearish momentum, despite some mixed signals from weekly and monthly indicators.
Who are in the management team of Prelude Therapeutics, Inc.?
As of March 2022, the management team of Prelude Therapeutics, Inc. is led by Mr. Kris Vaddi, who is the Chief Executive Officer, Founder, and Director.
What does Prelude Therapeutics, Inc. do?
Prelude Therapeutics, Inc. is a clinical-stage precision oncology company focused on developing small molecule therapies for cancer. It has a market cap of $52.37 million and reported a net profit loss of $32 million as of March 2025.
How big is Prelude Therapeutics, Inc.?
As of Jun 18, Prelude Therapeutics, Inc. has a market capitalization of 52.37 million, with net sales of 7.00 million and a net profit of -127.83 million over the latest four quarters. The company reported shareholder's funds of 131.46 million and total assets of 175.51 million as of Dec 24.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
